PCA
RCKT icon

Pallas Capital Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Pallas Capital Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.3K Buy
+19,635
New +$78K ﹤0.01% 816
2025
Q4 		– Sell
-11,321
Closed -$36.9K – 941
2025
Q3 		$36.9K Buy
+11,321
New +$35.7K ﹤0.01% 858

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pallas Capital Advisors's RCKT Position: Q1 2026 in Review

Pallas Capital Advisors opened a new position in Rocket Pharmaceuticals (RCKT) in Q1 2026: 19,635 shares worth $70.3K. The stake represents ﹤0.01% of the portfolio and ranks #816 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in RCKT as recently as Q3 2025.

Pallas Capital Advisors first reported a position in RCKT in Q3 2025 and has held it in 2 quarters since. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Pallas Capital Advisors held 19,635 shares of Rocket Pharmaceuticals worth $70.3K as of Q1 2026.
  • Rocket Pharmaceuticals was a new Pallas Capital Advisors position in Q1 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #816 holding.
  • Pallas Capital Advisors first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.